Treatment of BK Virus-Associated Hemorrhagic Cystitis

First-Line Management Approaches

Reduction of immunosuppressive medications is the primary treatment strategy for BK virus-associated hemorrhagic cystitis and nephropathy, particularly when BK viral load in plasma persistently exceeds 10,000 copies/mL, as recommended by the American Society of Transplantation 1, 2
Decreasing immunosuppressive medication is the cornerstone of treatment for BK virus-related complications, allowing the immune system to control viral replication, according to the American Society of Transplantation 1
This approach should be implemented with careful monitoring of graft function to prevent rejection, as suggested by the American Society of Transplantation 1
Regular monitoring of BK viral load by quantitative plasma nucleic acid testing (NAT) is essential to guide treatment decisions, as recommended by the American Society of Transplantation 1

Aggressive hydration to maintain adequate urine output and dilute irritants is recommended by the National Comprehensive Cancer Network 3

Low-dose intravenous cidofovir (1 mg/kg weekly without probenecid) has shown efficacy with complete response rates of 67-86% in BK virus-associated hemorrhagic cystitis, but caution is advised due to significant nephrotoxicity risk, particularly concerning in patients already experiencing BK virus nephropathy, as reported in Clinical Infectious Diseases 4
Monitor renal function closely with blood urea nitrogen, creatinine, and urinalysis before each infusion, as recommended by the Centers for Disease Control and Prevention 5
Foscarnet is an alternative for patients who cannot tolerate cidofovir due to nephrotoxicity, as suggested by the Infectious Diseases Society of America 6
Foscarnet is associated with electrolyte abnormalities requiring close monitoring, as reported in MMWR Recommendations and Reports 5

Regular quantitative BK virus testing in plasma and urine to assess treatment response is recommended by the Infectious Diseases Society of America 7, 8
Frequent assessment of serum creatinine, electrolytes, and urinalysis is necessary to monitor renal function, as suggested by Clinical Infectious Diseases 4
More intensive monitoring (twice weekly) during induction therapy and weekly thereafter is recommended by the Centers for Disease Control and Prevention 5

Nephrotoxicity from cidofovir treatment may worsen existing BK virus nephropathy, as reported in Clinical Infectious Diseases 4
Electrolyte abnormalities, particularly with foscarnet (hypocalcemia, hypophosphatemia, hypomagnesemia), require close monitoring, as reported in Clinical Infectious Diseases 4
Myelosuppression with systemic antiviral therapy is a potential complication, as reported in Praxis Medical Insights 6